文献速递流行病学与生物统计临床试验与 GCP

SGLT2抑制剂按肾小球滤过率和白蛋白尿分层的肾脏结局:一项meta分析

SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.
PubMed 文献 · JAMA · 2026-01-01

该meta分析纳入10项随机双盲安慰剂对照试验共70 361例参与者,评估SGLT2抑制剂对慢性肾脏病进展的影响是否受基线eGFR或白蛋白尿程度修饰。结果显示SGLT2抑制剂降低慢性肾脏病进展风险(HR 0.62,95%CI 0.57-0.68),且不受基线eGFR或白蛋白尿分层影响,包括4期慢性肾脏病或微量白蛋白尿患者。

要点

  • SGLT2抑制剂降低慢性肾脏病进展风险,HR 0.62(95%CI 0.57-0.68)。
  • 肾脏保护作用不受基线eGFR分层影响,趋势P=0.16。
  • 肾脏保护作用不受基线白蛋白尿分层影响,趋势P=0.49。

核心结论

  • SGLT2抑制剂降低慢性肾脏病进展风险,且不受基线eGFR或白蛋白尿影响,包括4期慢性肾脏病或微量白蛋白尿患者。

研究设计与样本

  • 纳入SMART-C联盟中10项随机双盲安慰剂对照试验,每组至少500例、随访至少6个月,共70 361例参与者(平均[SD]年龄64.8[8.7]岁;女性24 595例[35.0%])。
  • 采用逆方差加权meta分析合并各试验的治疗效应。

主要发现

  • 共2314例(3.3%)发生慢性肾脏病进展,988例(1.4%)达到肾衰竭。
  • SGLT2抑制剂降低慢性肾脏病进展风险(25.4 vs 40.3事件/1000患者年;HR 0.62,95%CI 0.57-0.68)。
  • 按基线eGFR分层:≥60 mL/min/1.73 m2 HR 0.61(95%CI 0.52-0.71);45至<60 mL/min/1.73 m2 HR 0.57(95%CI 0.47-0.70);30至<45 mL/min/1.73 m2 HR 0.64(95%CI 0.54-0.75);<30 mL/min/1.73 m2 HR 0.71(95%CI 0.60-0.83);趋势P=0.16。
  • 按基线白蛋白尿分层:≤30 mg/g HR 0.58(95%CI 0.44-0.76);>30-300 mg/g HR 0.74(95%CI 0.57-0.96);>300 mg/g HR 0.57(95%CI 0.52-0.64);趋势P=0.49。
  • SGLT2抑制剂降低单纯肾衰竭风险(HR 0.66,95%CI 0.58-0.75)。

关键数值与推荐

  • SGLT2抑制剂组慢性肾脏病进展事件率为25.4事件/1000患者年,安慰剂组为40.3事件/1000患者年。
  • 各eGFR和UACR亚组中SGLT2抑制剂均降低eGFR年下降速率,包括按有无糖尿病分别分析时。

临床怎么用

  • 作者认为,SGLT2抑制剂可常规用于改善2型糖尿病、慢性肾脏病或心力衰竭患者全 spectrum 肾功能范围内的肾脏结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce chronic kidney disease (CKD) progression in individuals with type 2 diabetes, CKD, or heart failure. However, their effects in those with stage 4 CKD or little to no albuminuria remain uncertain. OBJECTIVE: To assess whether estimated glomerular filtration rate (eGFR) or degree of albuminuria, measured by urinary albumin to creatinine ratio (UACR), modifies the effects of SGLT2 inhibitors on kidney outcomes. DATA SOURCES: SGLT2 inhibitor trials participating in the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium (SMART-C). STUDY SELECTION: Randomized, double-blind, placebo-controlled trials within SMART-C evaluating an SGLT2 inhibitor with label indications for reducing CKD progression including at least 500 participants in each group with at least 6 months of follow-up. DATA EXTRACTION AND SYNTHESIS: Treatment effects in individual trials were pooled using inverse variance-weighted meta-analysis. MAIN OUTCOMES AND MEASURES: CKD progression, defined as kidney failure, at least 50% reduction in eGFR, or death due to kidney failure. Other outcomes included annual rate of eGFR decline and kidney failure. RESULTS: Among 70 361 participants (mean [SD] age, 64.8 [8.7] years; 24 595 [35.0%] females) in 10 randomized trials, 2314 (3.3%) experienced CKD progression and 988 (1.4%) reached kidney failure. SGLT2 inhibitors reduced the risk of CKD progression (25.4 vs 40.3 events per 1000 patient-years; hazard ratio [HR], 0.62 [95% CI, 0.57-0.68]), irrespective of baseline eGFR (HR of 0.61 [95% CI, 0.52-0.71] for eGFR ≥60 mL/min/1.73 m2; 0.57 [95% CI, 0.47-0.70] for eGFR of 45 to <60 mL/min/1.73 m2; 0.64 [95% CI, 0.54-0.75] for eGFR of 30 to <45 mL/min/1.73 m2; and 0.71 [95% CI, 0.60-0.83] for eGFR <30 mL/min/1.73 m2; P for trend = .16) and baseline albuminuria (HR of 0.58 [95% CI, 0.44-0.76] for albuminuria ≤30 mg/g; 0.74 [95% CI, 0.57-0.96] for >30-300 mg/g; and 0.57 [95% CI, 0.52-0.64] for more than 300 mg/g; P for trend = .49). Although the magnitude of protection varied, SGLT2 inhibitors reduced the annual rate of eGFR decline across all eGFR and UACR subgroups, including when participants with and without diabetes were analyzed separately. SGLT2 inhibitors also reduced the risk of kidney failure alone (HR, 0.66 [95% CI, 0.58-0.75]). CONCLUSIONS AND RELEVANCE: In this meta-analysis, SGLT2 inhibitors were found to lower the risk of CKD progression regardless of baseline eGFR or albuminuria, including in patients with stage 4 CKD or minimal albuminuria, supporting their routine use to improve kidney outcomes across the full spectrum of kidney function among patients with type 2 diabetes, CKD, or heart failure.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Neuen BL, Fletcher RA, Anker SD, et al. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis. JAMA. 2026. PMID: 41203232. doi:10.1001/jama.2025.20834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。